Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cue Biopharma Inc Market Cap
Based on ratings from 1 stock analysts, the Cue Biopharma Inc stock price is expected to increase by 650% in 12 months. This is calculated by using the average 12-month stock price forecast for Cue Biopharma Inc. The lowest target is $2 and the highest is $6. Please note analyst price targets are not guaranteed and could be missed completely.
CUE is a stock in Health Care which has been forecasted to be worth $4.2 as an average. On the higher end, the forecast price is $6 USD by Maury Raycroft from Jefferies and on the lower end CUE is forecasted to be $2 by Reni Benjamin from JMP Securities.
These are the latest 20 analyst ratings of CUE.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Stephen Willey Stifel | Buy | $4 | Maintains | Aug 20, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $3 | Maintains | Jul 26, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $2 | Maintains | Jul 26, 2024 |
| Leland Gershell Oppenheimer | Outperform | $10 | Maintains | Apr 9, 2024 |
| Stephen Willey Stifel | Buy | $8 | Maintains | Apr 9, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $8 | Reiterates | Apr 3, 2024 |
| Maury Raycroft Jefferies | Buy | $6 | Initiates | Mar 13, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $8 | Maintains | Nov 6, 2023 |
| Mark Breidenbach Oppenheimer | Outperform | $10 | Assumes | Jun 26, 2023 |
| Stephen Willey Stifel | Buy | $8 | Reiterates | Jun 15, 2023 |
| Reni Benjamin JMP Securities | Outperform | $15 | Reiterates | May 15, 2023 |
| Stephen Willey Stifel | Buy | $8 | Maintains | Mar 22, 2023 |
| Mark Breidenbach Oppenheimer | Outperform | $10 | Reiterates | Mar 22, 2023 |
| Edward Tenthoff Piper Sandler | Overweight | $7 | Initiates | Nov 21, 2022 |
| Mark Breidenbach Oppenheimer | Outperform | $10 | Maintains | Aug 24, 2022 |
| Mark Breidenbach Oppenheimer | Outperform | $26 | Maintains | Mar 21, 2022 |
| Robin Garner Craig-Hallum | Buy | $26 | Maintains | Mar 18, 2022 |
Berenberg | Buy | Initiates | Nov 24, 2020 | |
Stifel | Buy | $30 | Maintains | May 20, 2020 |
Oppenheimer | Outperform | $32 | Maintains | May 20, 2020 |
When did it IPO
2018
Staff Count
53
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Daniel R. Passeri J.D., M.Sc.
Market Cap
$26.9M
In 2023, CUE generated $5.5M in revenue, which was a increase of 340.96% from the previous year. This can be seen as a signal that CUE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 19 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2024 Earnings Conference Call August 19, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Ren Benjamin - Citizens JMP Maury Raycroft - Jefferies Leland Gershell - Oppenheimer Edward Tenthoff - Piper Sandler Operator Good day, and welcome to the Cue Biopharma Second Quarter 2024 Earnings Call. All participants will be in a listen-only mode.
Mon, 19 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second quarter 2024.
Wed, 14 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago.
Thu, 30 May 2024
Sentiment - POSITIVE
Source - InvestorPlace
Summary - Human life expectancy has doubled since the 1900s, mostly attributed to advancements in lifestyle, living standards and medicine. Thanks to biotech companies that produce transformative drugs and treatments, we now have the collective ability to combat diseases that used to bring entire nations down.
Wed, 08 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.
Wed, 24 Apr 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
